What is the recommended protocol for switching from levetiracetam (Keppra) to brivaracetam (Briviact)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Levetiracetam (Keppra) to Brivaracetam (Briviact)

An overnight switch from levetiracetam to brivaracetam at a conversion ratio of 10:1 to 15:1 is safe, well-tolerated, and the recommended approach for most patients. 1, 2, 3

Conversion Protocol

Recommended Conversion Ratio

  • Use a 10:1 to 15:1 conversion ratio (levetiracetam:brivaracetam)
  • For example: Levetiracetam 1000 mg/day converts to brivaracetam 100 mg/day (10:1) or 67-100 mg/day (15:1)
  • The FDA-approved starting dose for adults is 50 mg twice daily (100 mg/day), with a range of 50-200 mg/day 1

Switching Method

Perform an overnight (immediate) switch rather than gradual cross-titration:

  • Stop levetiracetam on day 1
  • Start brivaracetam at the calculated dose on day 2
  • No titration period is required when initiating brivaracetam 1
  • This approach has been validated in multiple real-world studies showing excellent safety and tolerability 2, 4

Dosing Specifics

For adults (≥16 years):

  • Initial dose: 50 mg twice daily (100 mg/day)
  • Maintenance range: 25-100 mg twice daily (50-200 mg/day)
  • Adjust based on clinical response and tolerability 1

For pediatric patients weighing ≥50 kg:

  • Follow adult dosing guidelines
  • For patients <50 kg, use weight-based dosing per FDA label 1

Expected Outcomes

Seizure Control

  • Retention rates: 88.6% at 6 months, 83.9% at 12 months 5
  • Seizure freedom: 72.7% at 6 months, 58.1% at 12 months in conversion monotherapy 5
  • Overall seizure frequency improves in 26.8% of patients, remains stable in 61%, and worsens in only 12.2% 2

Neuropsychiatric Adverse Effects

This is the primary reason for switching and shows the most dramatic improvement:

  • 76% of patients experience improvement in levetiracetam-related neuropsychiatric symptoms after switching to brivaracetam 2
  • Improvements are particularly notable in irritability, aggression, mood disturbances, and behavioral problems 6, 4
  • In pediatric patients, 60% report improved tolerability, especially regarding mood, attention, and irritability 6

Safety Profile

  • Discontinuation rate: Only 4.5-19.5% due to adverse events 5, 2
  • Most common adverse events: somnolence, dizziness, fatigue (similar to levetiracetam but generally better tolerated) 2, 7
  • No serious adverse events reported in most switching studies 2

Special Considerations

Patients with Prior Psychiatric History

  • A history of psychiatric illness predicts neuropsychiatric side effects with levetiracetam but NOT with brivaracetam (p=0.001) 4
  • This makes brivaracetam particularly valuable for patients with baseline psychiatric comorbidities

Patients with Intellectual Disabilities

  • Switching is equally safe and effective in patients with intellectual disabilities compared to those without 4
  • Over 90% remain on brivaracetam after 12 months regardless of intellectual disability status 4

Hepatic Impairment

If hepatic impairment is present:

  • Reduce initial dose to 25 mg twice daily (50 mg/day)
  • Maximum maintenance dose: 75 mg twice daily (150 mg/day) 1

Concomitant Rifampin

  • Double the brivaracetam dose (increase by up to 100%) if patient is taking rifampin 1

Common Pitfalls to Avoid

  1. Do not perform gradual cross-titration - The overnight switch is both safe and preferred, avoiding prolonged exposure to levetiracetam's neuropsychiatric effects 2

  2. Do not use a 1:1 conversion ratio - This will result in overdosing; the correct ratio is 10:1 to 15:1 3

  3. Do not expect immediate seizure improvement - While neuropsychiatric symptoms often improve rapidly, seizure control may take several weeks to assess 5

  4. Do not abruptly discontinue brivaracetam if switching back - Taper over 1-4 weeks depending on dose to minimize seizure risk 1

  5. Be aware that 19% may experience worsened adverse effects - Have a plan to switch back to levetiracetam if needed 6

Monitoring After Switch

  • Assess neuropsychiatric symptoms within the first week (most improvements occur rapidly)
  • Evaluate seizure control at 3 months, 6 months, and 12 months
  • Monitor for somnolence, dizziness, and fatigue (most common adverse events)
  • Consider dose adjustment based on clinical response between 50-200 mg/day 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.